Biotech Values

[DewDiligence]

Botulinum toxin may work in dry/wet AMD:

https://www.businesswire.com/news/home/20211130005143/en

These three patents cover neuromodulator-based methods for: (1) treating and retarding the progression of dry macular degeneration wherein the drug product is injected into the para orbital region outside the eye or eye region and target anatomic structures inside the eye: (2) increasing the potency and duration of action of anti-VEGF agents effect on intra retinal edema; and (3) treating and slowing the development of macular degeneration and preserving the choriocapillaris, retinal pigment epithelium, and long-term function of other anatomic structures inside the eye.

Dr. Borodic, the author of the above patents, licensed a suite of botulinum-toxin patents to RVNC in 2016 (#msg-123060641, #msg-123060737), but the new AMD patents above are not part of the package licensed to RVNC.